PMID- 31625449
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Print)
IS  - 1557-9883 (Linking)
VI  - 13
IP  - 5
DP  - 2019 Sep-Oct
TI  - Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with 
      Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile 
      Dysfunction.
PG  - 1557988319882597
LID - 10.1177/1557988319882597 [doi]
LID - 1557988319882597
AB  - This meta-analysis was performed to evaluate the efficacy and safety of tadalafil 
      plus tamsulosin compared with tadalafil alone in treating men with benign 
      prostatic hyperplasia (BPH) and erectile dysfunction (ED) after 12 weeks' 
      treatment. Systematic review was carried out using the Preferred Reporting Items 
      for Systematic Reviews and Meta-analyses. MEDLINE, EMBASE, and the Cochrane 
      Controlled Trials Register were searched to collect randomized controlled trials. 
      The references of related articles were also searched. Four articles including 
      621 patients were involved in the analysis. The study identified that 
      combination-therapy had significant improvements in total international prostate 
      symptom score (IPSS), quality of life (QoL) and maximum urine flow rate (Qmax) 
      compared with monotherapy, and there were no obvious significance in respects of 
      post-void residual volume, international index of erectile function and IPSS 
      storage. The difference of total IPSS was mainly reflected in the change of IPSS 
      voiding. For safety, combination-therapy had a higher incidence rate of any 
      adverse events (AEs) and discontinuation due to AEs than monotherapy with the 
      exception of pain. In conclusion, the combination of tadalafil and tamsulosin 
      provided a better improvement of IPSS voiding, QoL and Qmax compared with 
      tadalafil alone in treating men with BPH and ED, and the former therapy appeared 
      to show a higher incidence of AEs.
FAU - Zhou, Zhongbao
AU  - Zhou Z
AD  - Binzhou Medical University, Yantai, Shandong, China.
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Zheng, Xuesong
AU  - Zheng X
AD  - Department of Urology, Qixia People's Hospital, Yantai, Shandong, China.
FAU - Wu, Jitao
AU  - Wu J
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Gao, Zhenli
AU  - Gao Z
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Xu, Zhunan
AU  - Xu Z
AD  - Binzhou Medical University, Yantai, Shandong, China.
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Cui, Yuanshan
AU  - Cui Y
AUID- ORCID: 0000-0002-9810-8145
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
AD  - Department of Urology, Beijing TianTan Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - 742SXX0ICT (Tadalafil)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
MH  - Aged
MH  - Drug Therapy, Combination
MH  - Erectile Dysfunction/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/*therapeutic use
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Tadalafil/*therapeutic use
MH  - Tamsulosin/*therapeutic use
MH  - Treatment Outcome
MH  - Vasodilator Agents/*therapeutic use
PMC - PMC6801893
OTO - NOTNLM
OT  - benign prostatic hyperplasia
OT  - erectile dysfunction
OT  - meta-analysis
OT  - tadalafil
OT  - tamsulosin
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/10/19 06:00
MHDA- 2020/09/25 06:00
PMCR- 2019/10/18
CRDT- 2019/10/19 06:00
PHST- 2019/10/19 06:00 [entrez]
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2019/10/18 00:00 [pmc-release]
AID - 10.1177_1557988319882597 [pii]
AID - 10.1177/1557988319882597 [doi]
PST - ppublish
SO  - Am J Mens Health. 2019 Sep-Oct;13(5):1557988319882597. doi: 
      10.1177/1557988319882597.